/ /

Mark Fuerst
Ethnic disparities evaporate with DAA treatment of hepatitis C infections
Hispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.
HIV/HCV infected drug users an ideal population for direct-acting antiviral use
Those using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.
Breaking barriers to hepatitis C treatment in the DAA era
Targeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.
Eight-week drug combo regimen maintains SVR in real-world setting
Researchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
HCV-related liver disease on the rise in women
The benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Study: HCV week 4 viral load predicts DAA treatment response
Week 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.
Researchers: Hepatitis C virus control needs a public health approach
A new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.
DAAs safely treat chronic kidney disease in HCV patients
Direct-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
Primary care can manage hep C infections with DAAs
Primary care professionals can “substantially expand” HCV treatment in the community, according to new research.
DAAs improve patient and graft survival after liver transplant
Liver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.